Douglas Macdonald
CHDI Foundation · 44 works · 1,588 citations · h-index 22
Top works
- Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients
- Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding.
- Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression
- SCH-202676: An Allosteric Modulator of Both Agonist and Antagonist Binding to G Protein-Coupled Receptors
- Molecular Characterization of the Melanin-Concentrating Hormone/Receptor Complex: Identification of Critical Residues Involved in Binding and Activation
- The Role of Histidine-1 in Glucagon Action
- Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists
- A Profiling Platform for the Characterization of Transglutaminase 2 (TG2) Inhibitors
- Polyglutamine- and Temperature-Dependent Conformational Rigidity in Mutant Huntingtin Revealed by Immunoassays and Circular Dichroism Spectroscopy
- Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins
- Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease
- Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist.
- Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay
- TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy
- Meso scale discovery-based assays for the detection of aggregated huntingtin
- Photoaffinity Labeling of Mutant Neurokinin-1 Receptors Reveals Additional Structural Features of the Substance P/NK-1 Receptor Complex
- Further Definition of the Substance P (SP)/Neurokinin-1 Receptor Complex
- SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease
- Safety and Tolerability of Selisistat for the Treatment of Huntington’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (S47.004)
- Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtin